MedPath

Escitalopram for Agitation in Alzheimer's Disease

Phase 3
Active, not recruiting
Conditions
Dementia
Interventions
Drug: Placebo
Registration Number
NCT03108846
Lead Sponsor
JHSPH Center for Clinical Trials
Brief Summary

The purpose of this study is to evaluate the safety and efficacy of escitalopram for agitation in Alzheimer's dementia.

Detailed Description

This study is designed to examine the efficacy and safety of escitalopram as treatment for agitation in Alzheimer's dementia (AD) patients. Participants with clinically significant agitation, and their caregiver(s), will receive a structured psychosocial intervention. Participants not showing a response three weeks later will be randomized 1:1 to escitalopram (up to 15 mg/day) or a matching placebo. Participants will receive study drug or placebo for 12 weeks, with in-person and remote (phone/video) visits at weeks 3, 6, 9, and 12, and with telephone contacts between in-person and remote visits. Participants who do show a response to the psychosocial intervention will not be randomized to study drug but will be followed remotely.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
187
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlacebo1-3 capsules each containing placebo only once per day in the morning
EscitalopramEscitalopramEscitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
Primary Outcome Measures
NameTimeMethod
modified- Alzheimer's Disease Cooperative Study--Clinical Global Impression of Change (mADCS-CGIC)after 12 weeks

Clinical Global Impression of Change

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (29)

Banner Sun Health Research Institute

🇺🇸

Sun City, Arizona, United States

Biomedical Research Foundation

🇺🇸

Little Rock, Arkansas, United States

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

University of California Los Angeles/VA Greater Los Angeles Healthcare System

🇺🇸

Los Angeles, California, United States

University of Southern California Keck School of Medicine Memory and Aging Center

🇺🇸

Los Angeles, California, United States

Miami Jewish Health Systems

🇺🇸

Miami, Florida, United States

Kansas School of Medicine-Wichita Center for Clinical Research

🇺🇸

Wichita, Kansas, United States

Maryland VA Health Care System

🇺🇸

Baltimore, Maryland, United States

Johns Hopkins University School of Medicine, Bayview Medical Center

🇺🇸

Baltimore, Maryland, United States

Alzheimer Disease Center

🇺🇸

Quincy, Massachusetts, United States

Scroll for more (19 remaining)
Banner Sun Health Research Institute
🇺🇸Sun City, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.